Investment
Features
FeesSafety
Academy
More
Pluang+

HPC backs SEC's Regulation Crypto Assets, urges five key refinements for clearer token rules

Market News
19 Oct 2026
Blockonomi
View Source
Bullish
HPC backs SEC's Regulation Crypto Assets, urges five key refinements for clearer token rules

The Hyperliquid Policy Center (HPC) formally supports the SEC's proposed Regulation Crypto Assets, which aims to clarify token offerings and provide exemptions from state registration. HPC filed a comment letter recommending five refinements, including clearer rules on airdrops, secondary trading, safe harbor certifications, buybacks, and federal preemption. The proposal offers fundraising exemptions up to $75 million annually and a safe harbor to confirm when tokens are not investment contracts. HPC emphasizes the need for clear federal guidelines to prevent projects from launching abroad or excluding U.S. investors due to legal uncertainty, and plans to continue engaging with the SEC as the rule is finalized.

The Hyperliquid Policy Center's stance on SEC crypto regulation is the subject here, with Pluang market data providing context. For readers following major cryptocurrencies, 42 of 50 rose and 7 fell today. Notable movers include SNX at Rp3.868 (+4.20%), UNI at Rp131.773 (+3.10%), and SAND at Rp1.067 (+2.90%). This data is as of Oct 20, 2026 06:02 WIB.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
26 minutes ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
26 minutes ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
1 hour ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
2 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App